Clinical reports indicate that MGMT promoter is methylated, and thus suppressed, in about 21.5–35% of metastatic melanomas [119,121,122,123], which entails that inhibition of BRAF, MEK and HDAC could potentially benefit a large number of melanoma patients. Here, MAP2K7 is linked to melanoma.